SCHEMBL1103493

SCHEMBL1103493

c1ccc(-c2c3ccccc3c(-c3ccc(-c4c5ccccc5c(-c5ccc(-c6c7ccccc7c(-c7ccc8ccccc8c7)c7ccccc67)cc5)c5c4cnc4ccccc45)cc3)c3ccccc23)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 6/20 0.48
▸ ESR2 Q92731 5/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ PIK3CD O00329 1/20 0.41
▸ PIK3CA P42336 1/20 0.41
▸ PIK3CB P42338 1/20 0.41
▸ MTOR P42345 1/20 0.41
▸ PIK3CG P48736 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.40
▸ GPR3 P46089 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103484 1.00 ESR1 (0.48) ESR1ESR2SMN1; SMN2LMNAMAPT
SCHEMBL1103485 1.00 ESR1 (0.48) ESR1ESR2SMN1; SMN2LMNAMAPT
SCHEMBL1103381 1.00 ESR1 (0.48) ESR1ESR2SMN1; SMN2LMNAMAPT
SCHEMBL1103448 1.00 ESR1 (0.48) ESR1ESR2SMN1; SMN2LMNAMAPT
SCHEMBL1103455 1.00 ESR1 (0.48) ESR1ESR2SMN1; SMN2LMNAMAPT
SCHEMBL1103470 0.99 ESR1 (0.47) ESR1ESR2SMN1; SMN2LMNAMAPT
SCHEMBL1103500 0.99 ESR1 (0.47) ESR1ESR2SMN1; SMN2LMNAMAPT
SCHEMBL1103385 0.99 ESR1 (0.47) ESR1ESR2SMN1; SMN2LMNAMAPT
SCHEMBL1103488 0.97 ESR1 (0.46) ESR1ESR2SMN1; SMN2LMNAMAPT
SCHEMBL1103482 0.97 ESR1 (0.46) ESR1ESR2SMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 ESR1 1038/4885ESR2 576/4885SMN1; SMN2 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback